Business Description
ODI Pharma AB
ISIN : SE0013409760
Share Class Description:
XSAT:ODI: Ordinary SharesTotal Employee Number:
1Compare
Compare
Traded in other countries / regions
ODI.Sweden6OD.Germany IPO Date
2020-01-23Description
ODI Pharma AB is a provider of medicinal cannabis. It offers its products to pharmacies, specialty clinics, and hospitals.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.17 | |||||
Interest Coverage | 0.55 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 6.05 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 100.4 | |||||
3-Year EBITDA Growth Rate | 16.3 | |||||
3-Year EPS without NRI Growth Rate | 12.6 | |||||
3-Year FCF Growth Rate | 28.6 | |||||
3-Year Book Growth Rate | -66.4 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 62.38 | |||||
9-Day RSI | 52.93 | |||||
14-Day RSI | 48.11 | |||||
3-1 Month Momentum % | -18.13 | |||||
6-1 Month Momentum % | -11.31 | |||||
12-1 Month Momentum % | 13.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.2 | |||||
Quick Ratio | 1.2 | |||||
Cash Ratio | 0.48 | |||||
Days Sales Outstanding | 39.83 | |||||
Days Payable | 62.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 28.94 | |||||
Operating Margin % | 1.3 | |||||
Net Margin % | -0.93 | |||||
EBITDA Margin % | 1.44 | |||||
FCF Margin % | 2.51 | |||||
OCF Margin % | 2.51 | |||||
ROE % | -26.1 | |||||
ROA % | -3.46 | |||||
ROIC % | 10.97 | |||||
3-Year ROIIC % | 74.95 | |||||
ROC (Joel Greenblatt) % | 5423.08 | |||||
ROCE % | 40.02 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Price-to-Owner-Earnings | 57.5 | |||||
PS Ratio | 1.57 | |||||
PB Ratio | 25.93 | |||||
Price-to-Tangible-Book | 25.4 | |||||
Price-to-Free-Cash-Flow | 63.5 | |||||
Price-to-Operating-Cash-Flow | 63.5 | |||||
EV-to-EBIT | 100.28 | |||||
EV-to-EBITDA | 99.57 | |||||
EV-to-Revenue | 1.43 | |||||
EV-to-FCF | 51.16 | |||||
Price-to-GF-Value | 0.27 | |||||
| Price-to-Net-Current-Asset-Value | 25.4 | |||||
Earnings Yield (Greenblatt) % | 0.99 | |||||
FCF Yield % | 1.59 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ODI Pharma AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 29.618 | ||
| EPS (TTM) (kr) | -0.01 | ||
| Beta | 1.2338 | ||
| 3-Year Sharpe Ratio | 0.14 | ||
| 3-Year Sortino Ratio | 0.32 | ||
| Volatility % | 169.63 | ||
| 14-Day RSI | 48.11 | ||
| 14-Day ATR (kr) | 0.384518 | ||
| 20-Day SMA (kr) | 2.415 | ||
| 12-1 Month Momentum % | 13.74 | ||
| 52-Week Range (kr) | 1 - 5.45 | ||
| Shares Outstanding (Mil) | 18.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ODI Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ODI Pharma AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-04 15:00 | In 142 days | ||
| First quarter earnings results for 2027 | 2026-11-27 | In 134 days | ||
| Annual report for 2026 | 2026-11-20 | In 127 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-27 | In 42 days | ||
| Third quarter earnings results for 2026 | 2026-05-28 | 3.80 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-02-26 | 3.54 (+0.00%) | ||
| General meeting for 2025 | 2025-12-05 15:00 | 1.60 (+3.23%) | ||
| First quarter earnings results for 2026 | 2025-11-27 | 1.57 (+15.44%) | ||
| Annual report for 2025 | 2025-11-21 | 1.04 (-9.57%) | ||
| Fourth quarter earnings results for 2025 | 2025-08-28 | 1.59 (+1.27%) |
Show
Entries
ODI Pharma AB Frequently Asked Questions
What is ODI Pharma AB(XSAT:ODI)'s stock price today?
The current price of XSAT:ODI is kr2.54. The 52 week high of XSAT:ODI is kr5.45 and 52 week low is kr1.00.
When is next earnings date of ODI Pharma AB(XSAT:ODI)?
The next earnings date of ODI Pharma AB(XSAT:ODI) is 2026-08-27.
Does ODI Pharma AB(XSAT:ODI) pay dividends? If so, how much?
ODI Pharma AB(XSAT:ODI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on ODI Pharma AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers